Primary objective: To describe the safety profile of a refrigerator-stable formulation of VARIVAX® as a first single dose injection in 12 to 15 month-old infants in the 42-day follow-up period post-vaccination. Secondary objectives: NA
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
500
Unnamed facility
Amboise, France
Unnamed facility
Ancenis, France
Unnamed facility
Betton, France
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Châteaubriant, France
Unnamed facility
Courbevoie, France
Unnamed facility
Essey-lès-Nancy, France
Unnamed facility
Floirac, France
Unnamed facility
Fougères, France
Unnamed facility
Garches, France
Unnamed facility
Gradignan, France
...and 15 more locations